GHRH analogues and growth hormone secretagogues used in endocrine pharmacology and analytical research, each with a lot-specific certificate of analysis.
Two receptor systems drive this category. GHRH analogues such as tesamorelin and CJC-1295 act on the growth hormone-releasing hormone receptor. Growth hormone secretagogues such as ipamorelin act on a different receptor, the one also targeted by ghrelin and GHRP-6. Comparing the two pathways is a common reason labs keep both types of reference material on hand.
Tesamorelin is the active ingredient of an FDA-approved medicine, which gives it a deep clinical literature; our tesamorelin is a research reference material, not that medicine. Much of the recent literature on all three peptides comes from anti-doping laboratories developing detection methods, which makes their analytical behavior well documented.
| Material | Class | Where it appears in research | Current lot purity |
|---|---|---|---|
| Tesamorelin 10mg | GHRH (1-44) analogue | GHRH-receptor pharmacology, comparator for newer analogues | 99.82% |
| Tesamorelin 20mg | GHRH (1-44) analogue | Multi-assay work from a single lot | 99.03% |
| CJC-1295 no DAC / Ipamorelin 10mg | GHRH analogue + secretagogue blend | Comparing GHRH-receptor and secretagogue-receptor signaling | 99.76% |
Purity is the HPLC result for the lot currently shipping. See every published certificate in our lab results dataset.
Tesamorelin is the reference choice when you need a GHRH analogue with an extensive published record. The CJC-1295 no DAC / ipamorelin blend pairs a shortened GHRH analogue with a selective secretagogue. Note that most CJC-1295 clinical data describe the DAC form, a different and heavier molecule.
Each lot is tested by an independent laboratory before release, with HPLC purity and an identity result on the certificate of analysis. The lot number in your order confirmation matches a specific certificate, which you can look up on the lot verification page. Lots below 99% purity are not released.
GHRH analogues, like tesamorelin and CJC-1295, bind the growth hormone-releasing hormone receptor. Secretagogues, like ipamorelin, bind the growth hormone secretagogue receptor, the same receptor as ghrelin. They are separate pathways that labs often study side by side.
The 20mg vial suits labs planning several experiments from one characterized lot, which removes lot-to-lot variation from comparisons. The 10mg vial suits single studies. Each size has its own certificate of analysis.
No. The DAC version carries a drug affinity complex that binds albumin, giving it a larger mass and a far longer half-life in published studies. The no-DAC form, also called modified GRF (1-29), is a different reference material.
CJC-1295 vs tesamorelin: a research comparisonCJC-1295 research backgroundIpamorelin research background
Tissue-repair research peptidesMitochondrial & metabolic research compoundsNeuropeptide research compounds
Browse all research materials →